Key result
Genotype-specific treatments for LQT1, LQT2, and LQT3 offer novel strategies to prevent sudden cardiac death.
Why the study?
Understanding the molecular mechanisms underlying LQTS could help optimize genotype-specific treatments to prevent sudden cardiac death.
This review highlights the molecular mechanisms of Long QT syndrome and the potential for genotype-specific therapies to prevent sudden cardiac death.
These strategies should not yet change LQTS practice; leaves open the need for prospective trials to confirm benefit.
Long QT syndrome (LQTS) is a cardiovascular disorder characterized by an abnormality in cardiac repolarization leading to a prolonged QT interval and T-wave irregularities on the surface electrocardiogram. It is commonly associated with syncope, seizures, susceptibility to torsades de pointes, and risk for sudden death. LQTS is a rare genetic disorder and a major preventable cause of sudden cardiac death in the young. The availability of therapy for this lethal disease emphasizes the importance of early and accurate diagnosis. Additionally, understanding of the molecular mechanisms underlying LQTS could help to optimize genotype-specific treatments to prevent deaths in LQTS patients. In this review, we briefly summarize current knowledge regarding molecular underpinning of LQTS, in particular focusing on LQT1, LQT2, and LQT3, and discuss novel strategies to study ion channel dysfunction and drug-specific therapies in LQT1, LQT2, and LQT3 syndromes.
No takes yet. Share an insight, caveat, or question.
Ponce‐Balbuena et al. (2021) studied this question. Genotype-specific treatments targeting the molecular mechanisms of LQT1, LQT2, and LQT3 syndromes offer novel strategies to manage ion channel dysfunction and prevent sudden cardiac death.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: